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Abstract
Background: We have a limited understanding of the biological underpinnings of symptoms in 
heart failure (HF), particularly in response to left ventricular assist device (LVAD) implantation.
Objective: Quantify the degree to which symptoms and biomarkers change in parallel from prior 
to implantation through the first 6 months after LVAD implantation in advanced HF.
Methods: This was a prospective cohort study of 101 patients receiving an LVAD for the 
management of advanced HF. Data on symptoms (dyspnea, early & subtle symptoms (HF Somatic 
Perception Scale), pain severity (Brief Pain Inventory), wake disturbance (Epworth Sleepiness 
Scale), depression (Patient Health Questionnaire) and anxiety (Brief Symptom Inventory)) and 
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peripheral biomarkers of myocardial stretch, systemic inflammation and hyper-volumetric 
mechanical stress were measured prior to implantation with a commercially-available LVAD, and 
again at 30, 90 and 180 days after LVAD implantation. Latent growth curve and parallel process 
modeling were used to describe changes in symptoms and biomarkers and the degree to which 
they change in parallel in response to LVAD implantation.
Results: In response to LVAD implantation, changes in myocardial stretch were closely 
associated with changes in early & subtle physical symptoms as well as depression, and changes 
in hyper-volumetric stress were closely associated with changes in pain severity and wake 
disturbances. Changes in systemic inflammation were not closely associated with changes in 
physical or affective symptoms in response to LVAD implantation.
Conclusions: These findings provide new insights into the many ways in which symptoms and 
biomarkers provide concordant or discordant information about LVAD response.
Introduction
In the management of advanced heart failure (HF), implantation of a left ventricular assist 
device (LVAD) is a common strategy as a bridge to transplantation or as destination therapy.
1 It is well-known that adults living with advanced HF experience considerable burden from 
physical symptoms like dyspnea and pain as well as affective symptoms like depression and 
anxiety.2 In general, physical and affective symptoms improve in response to LVAD 
implantation.3,4 There remains, however, a general disconnect between what can be 
measured objectively about HF pathogenesis and the level of symptoms experienced by 
patients living with HF; that is, several groups have provided evidence of the limited 
association between objective markers of HF (i.e. clinical characteristics, echocardiographic 
values, right heart catheterization parameters, exercise tolerance tests results and common 
biomarkers) and symptoms.5–12 Additionally, relationships between biomarkers of HF 
pathogenesis and symptoms are different comparing patients with advanced to patients with 
moderate HF.13
Because there is no one metric used to judge LVAD responsiveness, providers must integrate 
both objective and subjective data to personalize their appraisal of therapeutic response. But, 
discordance between symptoms and objective metrics is common and is associated with 
worse clinical outcomes in HF.14 Moreover, there is current concern over the way in which 
biomarkers are used in advanced HF,15 and common-but-catch-all patient-reported outcomes 
like quality of life in the context of advanced HF are poorly understood by providers and 
patients alike.16,17 Hence, there is more information needed to understand how specific 
symptoms and biomarkers change in response to LVAD, both independently and collectively, 
and gain insight into the complexity of LVAD response.
The purpose of this paper was to quantify the relationship between changes in physical and 
affective symptoms and changes in biomarkers of HF pathogenesis in response to LVAD 
implantation. We first characterized change in symptoms and biomarkers separately, and 
then quantified the degree to which symptoms and biomarkers change in parallel from prior 
to implantation through the first 6 months after LVAD implantation.
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This was a prospective cohort study focused on symptom and biological responses to LVAD 
implantation among adults with advanced HF (the Profiling Biobehavioral Responses to 
Mechanical Support in Advanced Heart Failure (PREMISE) study).18 Participants in the 
PREMISE study were ≥21 years of age and undergoing implantation of a commercially-
available continuous-flow LVAD as a bridge to heart transplantation or as destination 
therapy as the pre-implant strategy as designated by a multidisciplinary advanced HF 
selection committee. All participants met criteria for Interagency Registry for Mechanically 
Assisted Circulatory Support profiles 1–4.19 Patients were not eligible if they had a heart 
transplantation or an LVAD prior to enrollment, diagnosis of a major psychiatric illness or 
documented major cognitive impairment such as Alzheimer’s disease. Participants were 
recruited through an advanced HF center between April, 2012 and December, 2015. The 
study was reviewed and approved by our institutional review board; written informed 
consent was obtained from all participants.
Data Collection
Participants were consented for this study prior to LVAD implantation by a member of the 
research team who was not directly involved with patient care. Self-report symptom data and 
blood samples were collected a median of 5 days pre-implant, and again at 30, 90 and 180 
days after LVAD implantation. Clinical data, including HF parameters, laboratory values and 
co-morbid conditions, were extracted from a detailed review of medical records.
Symptoms
Dyspnea was measured using the HF Somatic Perception Scale (HFSPS).20 The HFSPS asks 
about how much the participant was bothered by common HF symptoms during the last 
week. Response options range from 0 (did not have symptom) followed by degree of bother 
ranging from 1 (not at all bothersome) to 5 (extremely bothersome). The 6-item HFSPS 
subscale for dyspnea was used in this analysis (range 0–30; higher scores indicate worse 
dyspnea). Cronbach’s alpha on the dyspnea scale was 0.89 in this study. The HFSPS also has 
a 7-item subscale for what was called “early & subtle” symptoms by the measure architect.20 
Early & subtle symptoms include having an upset stomach, early satiety, fatigue and cough 
(subscale range 0–35; higher scores indicate worse symptoms).20 Cronbach’s alpha on the 
early & subtle scale was 0.74 in this study. The HFSPS was chosen over alternative 
measures because of both the utility and predictive validity of the dyspnea and early & 
subtle sub-scales.20
The Brief Pain Inventory (BPI) was used as an assessment of pain severity.21 The BPI 
consists of 4 questions about pain severity (i.e. worst, least, average and current pain 
intensity), referring to pain that occurs anywhere in the body but excluding everyday minor 
aches. A pain severity score was then calculated (ranging from 1–10; 0 = no pain, and 10 = 
pain as bad as they could imagine). Cronbach’s alpha was 0.90 in this study.
Wake disturbances were measured using the 8-item Epworth Sleepiness Scale (ESS).22 The 
ESS asks participants to rate how likely they would be to fall asleep in 8 situations (e.g. 
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sitting and reading, watching television, sitting and talking to someone); response options 
range from 0 (would never fall asleep) to 3 (high chance). The ESS (range 0–24 with higher 
values indicating worse wake disturbances) correlates significantly with sleep latency 
measures.22 Cronbach’s alpha was 0.87 in this study.
Depression was measured using the 9-Item Patient Health Questionnaire (PHQ9).23 The 
PHQ9 scores each of the 9 related DSM-IV criteria providing four response options ranging 
from 0 (not at all) to 3 (nearly every day). The PHQ9 total score ranges from 0 to 27 with 
higher scores indicating worse depressive symptoms.23 Cronbach’s alpha was 0.81 in this 
study.
Anxiety was measured using the Brief Symptom Inventory (BSI).24 The BSI asks about 
feelings during the past seven days and provides five response options ranging from 0 (no) to 
4 (extreme). Subscale scores (ranging from 0 to 4) are calculated by adding the ratings and 
dividing the total by the number of items in the subscale (6 items for anxiety), with higher 
scores indicating higher anxiety. Cronbach’s alpha was 0.84 in this study.
Biomarkers
We used a multi-marker strategy25 that included metrics of myocardial stretch, systemic 
inflammation and hyper-volumetric stress. We quantified amino terminal pro-B-type 
natriuretic peptide (NTproBNP) as a measure of myocardial stretch (Cusabio Technology, 
Houston, TX) as NTproBNP is reduced after LVAD implantation.26 We quantified soluble 
tumor necrosis factor α receptor 1 (sTNFαR1) as a metric of systemic inflammation (R&D 
Systems, Minneapolis, MN) as sTNFαR1 is increased after LVAD implantation.27 Finally, 
we quantified the soluble form of suppression of tumorigenicity-2 (sST2), which is the 
soluble receptor for interleukin-33 and a metric of hyper-volumetric stress in HF (Critical 
Diagnostics, San Diego, CA) because it is elevated in advanced HF and also reduced in 
response to LVAD implantation.28 NTproBNP, sTNFαR1 and sST2 also have different 
cross-sectional relationships with physical symptoms comparing patients with advanced HF 
to those with moderate HF.13
Statistical Analysis
Means and standard deviations or counts and proportions were used to describe the sample. 
Latent growth curve modeling29 was performed to quantify change in symptoms and 
biomarkers independently across four time points from pre-implant to 180 days post-
implant. We performed multiphase growth modeling30 to capture pre-implant values as well 
as the two major phases of change observed in most measures; initial improvements 
observed between pre-implant and 30 days post implant (i.e. slope 1 or Δ1), and subsequent 
improvements between 30 and 180 days post implant (i.e. slope 2 or Δ2). In figures 1 and 2, 
pre-implant values are presented in means and standard errors; phases of change are 
presented as mean slope, standard error of the slope, and the significance of change as well 
as Cohen’s d to quantify the magnitude of change (≈ 0.2–0.3 is a small effect, ≈ 0.4–0.5 is a 
moderate effect, and ≥ 0.8 is a large).31 Parallel process modeling was then completed to 
quantity the degree of similarity/dissimilarity between changes in symptoms and changes in 
biomarkers in response to LVAD implantation; although minimal, missing data were handled 
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using maximum likelihood estimation. Parallel process modeling32,33 is an extension of 
growth curve modeling that entails quantifying two growth curves (i.e. one for the symptom 
and one of the biomarker) and random effects between intercepts and slopes of the two 
growth curves. Because this approach is based on structural equation modeling, fit statistics 
are used to judge similarity between change in symptoms and change in biomarkers over 
time. Thresholds for acceptable fit, and therefore closely associated change in this study, 
were considered a) a non-significant chi-square test, b) comparative fit index (CFI) ≥0.95, c) 
Tucker-Lewis index (TLI) ≥0.95, d) root mean square error of approximation (RMSEA) 
≤0.06, and e) a standardized root mean square residual (SRMR) of ≤ 0.08.34 Values of all of 
these metrics close to the cutoffs are needed to conclude that there is a relatively good fit. 
There is no standard approach for sample size considerations in growth modeling 
particularly in fields where there is a limited evidence base. With four symptom and four 
biomarker measurements, however, our n-to-items ratio exceeded sample size 
recommendations for related approaches (10:1).35 All statistical analyses were performed 
using StataMP v15 (College Station, Texas) and Mplus v8 (Los Angeles, California).
Results
The sample (n=101) was predominantly male and Caucasian, and slightly more than two-
thirds of participants received an LVAD with bridge to transplantation as the pre-implant 
strategy (Table 1). As a whole, the sample had the characteristics of advanced HF including 
poor contractility, high filling pressures and reduced function; many required inotropic 
support.
Changes in symptoms are presented in Figure 1. There were large and significant 
improvements in dyspnea (p<0.001) and early & subtle symptoms (p<0.001) in response to 
LVAD implantation with the vast majority of improvement occurring within the first 30 days 
after implantation followed by continued significant improvement through 180 days. There 
was a small but significant improvement in wake disturbances at 30 days (p=0.036) followed 
by continued significant improvement through 180 days (p<0.001). Pain severity took longer 
to improve in response to LVAD with only a small but significant improvement at 180 days 
compared with pre-implant pain (p=0.009). Overall, there were large improvements in 
depression (p<0.001) and anxiety (p<0.001) over the course of 180 days; the greatest 
improvements in affective symptoms occurred within the first 30 days after LVAD 
implantation.
Changes in biomarkers in response to LVAD implantation are presented in Figure 2. There 
was a small-to-moderate and significant reduction in NTproBNP at 180 days after LVAD 
implantation (p<0.001). There was a moderate and significant increase in sTNFαR1 in the 
first 30 days after implantation (p<0.001) followed by a moderate and significant reduction 
between 30 and 180 days after implantation (p=0.001). There was no change in sST2 at 30 
days (p=0.732) followed by a moderate reduction between 30 and 180 days after 
implantation (p<0.001).
The relationship between NTproBNP and dyspnea and early & subtle symptoms are 
represented in Figure 3. In response to LVAD implantation, change in myocardial stretch is 
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more closely associated with change in early & subtle symptoms as opposed to dyspnea. The 
relationships between sTNFαR1 and pain severity and wake disturbances are presented in 
Figure 4. In response to LVAD implantation, change in systemic inflammation was not 
closely associated with changes in either pain severity or wake disturbances. The 
relationships between sST2 and both pain severity and wake disturbances are presented in 
Figure 5. Change in hyper-volumetric stress is closely associated with change in both pain 
severity and wake disturbances. The relationship between NTproBNP and depression as well 
as the relationship between sST2 and anxiety are presented in Figure 6. Change in 
myocardial stretch is closely associated with change in depression whereas change in hyper-
volumetric stress is not closely associated with change in anxiety. There were no other 
examples of close association in comparisons between symptoms and biomarkers over time 
(data not shown).
Discussion
Our understanding of the biological underpinnings of symptoms in HF is quite limited. In 
this sample of 101 adults undergoing LVAD implantation for the management of advanced 
HF, we observed several ways in which changes in symptoms were closely associated with 
changes in peripheral biomarkers of HF pathogenesis. Specifically, we observed that 
changes in myocardial stretch as measured by NTproBNP were closely related to changes in 
early & subtle physical symptoms (e.g. having an upset stomach, early satiety, fatigue or 
cough) as well as depression, and that changes in hyper-volumetric stress as measured by 
sST2 were closely related to changes in both pain severity and wake disturbances. We also 
observed several ways in which changes in symptoms were seemingly unrelated to changes 
in peripheral HF biomarkers. For example, changes in symptoms were not related to changes 
in systemic inflammation as measured by sTNFαR1, and changes in dyspnea were not 
closely related to changes in myocardial stretch. These finding contribute to a growing body 
of HF symptom science and also point toward several future directions of clinical research.
In HF, myocardial stretch-secretion coupling from congestion is the dominant mechanism 
for elevated NTproBNP.36,37 Since LVADs work primarily by unloading the ventricle and 
enhancing cardiac output, it is not surprising that reductions in NTproBNP were closely 
associated with concomitant improvements in early & subtle symptoms that include those 
related to both vascular congestion (e.g. cough and early satiety) and reduced blood flow 
(e.g. fatigue). One reason why reductions in NTproBNP were not closely associated with 
concomitant improvements in dyspnea may be that the largest improvement in any symptom 
in response to LVAD involved dyspnea and in contrast the smallest improvement in any 
biomarker involved NTproBNP. van den Broek and colleagues have shown that in HF, 
depression is not associated significantly with NTproBNP.38 But, there are several common 
pathophysiological pathways between depression and HF including autonomic dysfunction 
and inflammation that explain, at least in part, why we observed close associations between 
change in depression and change in NTproBNP in response to LVAD implantation.39,40
In response to mechanical stress or injury, interleukin-33 and the cellular receptors thereof 
interact in mechanisms that are cardioprotective (i.e. reduce myocardial fibrosis, 
hypertrophy and apoptosis).41 As the soluble receptor of interleukin-33, sST2 acts as a 
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decoy receptor in HF pathogenesis and antagonizes what otherwise would be 
cardioprotective processes. Since sST2 is relevant to cardiomyocytes and fibroblasts, 
elevated levels in HF are viewed as indices of hyper-volumetric stress and also fibrosis, in 
addition to inflammation (since sST2 is a receptor of a cytokine).28 To the best of our 
knowledge, our finding of close associations between sST2 and pain severity and wake 
disturbances in response to LVAD implantation make a novel contribution to the field. In 
mice, interleukin-33 has been shown to mediate inflammatory hyper-nociception, a process 
that is mitigated by sST2.42 In advanced HF in general, pain frequently occurs in multiple 
sites and is not related to cardiac pain;43 but, the exact mechanisms of pain in HF have not 
been explicated. Since sST2 is a marker of mechanical stress, fibrosis and inflammation, 
these mechanisms and the regulators thereof may be helpful in exploring the origins of pain 
in HF in more detailed future studies. After LVAD implantation, there may be tradeoffs in 
the location and even origins of pain including non-cardiac pain, but overall pain severity 
was not improved significantly until 90 days after LVAD compared with pre-implant pain. 
Although not much is written about pain after LVAD, palliative care may be a way to 
optimize residual and post-operative pain management.44
Our group has shown previously that in a cross-sectional fashion sST2 is not associated 
significantly with wake disturbances in HF.13 In this study, we observed that improvements 
in wake disturbances were closely associated with concomitant improvements in hyper-
volumetric stress. Others have shown that in HF the major determinants of wake 
disturbances include poor sleep quality and worse functional class.45 Although not 
specifically tested in this study, it may be that reductions in volume overload improve sleep 
quality and subsequently reduce wake disturbances. Future mechanistic studies examining 
the interplay between sleep quality and wake disturbances, as well as the biological 
underpinnings thereof, are needed. We also observed that the large reductions in anxiety 
were not closely associated with concomitant reductions in sST2. The exact mechanism of 
anxiety in HF is not clear,46 although hypothalamic-pituitary-adrenal axis dysfunction has 
been proposed.47 Future research into the biological underpinnings of anxiety and HF 
should focus on the hypothalamic-pituitary-adrenal axis.
Given the pattern of initial worsening of systemic inflammation and the marked initial 
improvements in most symptoms, that lack of a strong association between sTNFαR1 and 
symptoms was not completely counterintuitive. Others have shown that the systemic 
inflammatory response was present for approximately two months post-surgery, and that 
higher levels of TNFα after LVAD are associated with other important events like bleeding.
48,49 Hence, sTNFαR1 may continue to be an important maker of systemic inflammation in 
HF and adverse outcomes; but, it may not necessarily be an important marker in 
understanding changes in symptoms post LVAD.
Given these collective insights, clinicians might expect to see similar changes in myocardial 
stretch and both early & subtle symptoms and depression but not dyspnea. Hence, residual 
dyspnea after LVAD may be a function of other issues such as unmitigated comorbid 
conditions. Further, patients with enduring pain or wake disturbances after LVAD may also 
have hyper-volumetric stress. In that way, these residual symptoms after LVAD may be a 
sign of unresolved congestion. Further, several important symptoms like dyspnea and 
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pathogenic processes like systemic inflammation may be best understood in isolation and 
not by integration into a symptom biology perspective.
Limitations
A limitation to this and other non-experimental studies is the inability to comment on the 
causal nature of relationships or specific mechanisms; at this point in the state of the science 
of HF symptom biology, however, our findings serve as novel and additive contributions and 
point towards several areas of future study explicated throughout the discussion. 
Additionally, this was a single center study of a sample with several homogenous 
characteristics including race and gender and our findings may not be generalizable. Future 
work of ours and other groups must extend to multiple centers and aim for better patient 
representation, as well as the influence of multiple chronic conditions (e.g. sleep disordered 
breathing) that are ubiquitous in advanced HF on symptom biology.
Conclusion
In response to LVAD implantation, changes in myocardial stretch were closely associated 
with changes in early & subtle physical symptoms as well as depression. Changes in hyper-
volumetric stress were closely associated with changes in pain severity and wake 
disturbances. These findings contribute to the growing body of HF symptom biology 
research.
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Figure 1: Changes in Physical and Affective Symptoms in Response to Left Ventricular Assist 
Device Implantation.
Mean values of each symptom are presented as rectangles and the whisker bars represent the 
95% confidence interval at each time point. The two diagonal lines for each graph represent 
the initial change between pre-implant and 30 days post implant (Δ1) and the subsequent 
change (Δ2) through 180 days after implantation. Latent growth estimates of pre-implant 
values (i for intercept) and both the initial and subsequent rates of change (Δ1 and Δ2) are 
presented along with the standard error and related p-values. Finally, effect sizes overall and 
for each phase of change are presented in Cohen’s d (d) along with the statistical 
significance of change over 180 days after LVAD implantation. Abbreviations: BPI = Brief 
Pain Inventory; BSI = Brief Symptom Inventory; ESS = Epworth Sleepiness Scale; HFSPS = 
Heart Failure Somatic Perception Scale; PHQ9 = 9-item Patient Health Questionnaire.
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Figure 2: Changes in Biomarkers in Response to Left Ventricular Assist Device Implantation.
Mean values of each biomarker are presented as the filled rectangle and the whisker bars 
represent the 95% confidence interval for each time point. Horizontal lines for each graph 
represent overall change (Δ) in the case of NTproBNP or the initial change between pre-
implant and 30 days post implant (Δ1) and the subsequent change (Δ2) through 180 days 
after implantation in the case of sTNFαR1 and sST2. Latent growth modeling estimates of 
pre-implant values (i for intercept) and phases of change are presented along with the 
standard error and related p-values. Finally, effect sizes overall or for each phase of change 
are presented in Cohen’s d (d). Raw values are presented to assist with interpretation. The 
natural log of biomarker levels is what was used in the analysis to approximate normality. 
Abbreviations: ln = natural logarithm; NTproBNP = amino terminal pro-B-type natriuretic 
peptide; sST2 = soluble form of suppression of tumorigenicity-2; sTNFαR1 = soluble tumor 
necrosis factor alpha receptor 1.
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Figure 3: Parallel Changes in Myocardial Stretch and Physical Symptoms in Response to Left 
Ventricular Assist Device Implantation.
Mean values of biomarkers (leftward y-axes) and symptoms (rightward y-axes) are 
presented as the filled rectangle and the whisker bars represent the 95% confidence interval 
for each time point. Horizontal lines (dashed lines for biomarkers, solid lines for symptoms) 
for each graph represent overall change between pre-implant and 180 days post implant. 
Thresholds for acceptable fit for CFI and TLI are ≥ 0.95, RMSEA = ≤0.06 and SRMR ≤ 
0.08. Abbreviations: CFI = comparative fit indices; HFSPS = heart failure somatic 
perception scale; lnNTproBNP = natural log of amino terminal pro-B-type natriuretic 
peptide; RMSEA = root mean square errors of approximation; SRMR = standardized root 
mean square residual; TLI = Tucker-Lewis indices.
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Figure 4: Parallel Changes in Systemic Inflammation and both Pain Severity and Wake 
Disturbances in Response to Left Ventricular Assist Device Implantation.
Mean values of biomarkers (leftward y-axes) and symptoms (rightward y-axes) are 
presented as the filled rectangle and the whisker bars represent the 95% confidence interval 
for each time point. Horizontal lines (dashed lines for biomarkers, solid lines for symptoms) 
for each graph represent overall change between pre-implant and 180 days post implant. 
Thresholds for acceptable fit for CFI and TLI are ≥ 0.95, RMSEA = ≤0.06, and SRMR ≤ 
0.08. Abbreviations: BPI = Brief Pain Inventory; CFI = comparative fit indices; ESS = 
Epworth Sleepiness Scale; lnsTNFαR1 = natural log of soluble tumor necrosis factor alpha 
receptor 1; RMSEA = root mean square errors of approximation; SRMR = standardized root 
mean square residual; TLI = Tucker-Lewis indices.
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Figure 5: Parallel Changes in Hyper-volumetric Stress and both Pain Severity and Wake 
Disturbances in Response to Left Ventricular Assist Device Implantation.
Mean values of biomarkers (leftward y-axes) and symptoms (rightward y-axes) are 
presented as the filled rectangle and the whisker bars represent the 95% confidence interval 
for each time point. Horizontal lines (dashed lines for biomarkers, solid lines for symptoms) 
for each graph represent overall change between pre-implant and 180 days post implant. 
Thresholds for acceptable fit for CFI and TLI are ≥ 0.95, RMSEA = ≤0.06, and SRMR ≤ 
0.08. Abbreviations: BPI = Brief Pain Inventory; CFI = comparative fit indices; ESS = 
Epworth Sleepiness Scale; lnsST2 = natural log of soluble form of suppression of 
tumorigenicity-2; RMSEA = root mean square errors of approximation; SRMR = 
standardized root mean square residual; TLI = Tucker-Lewis indices.
Lee et al. Page 16













Figure 6: Parallel Changes in Myocardial Stretch and Depression, and Hyper-volumetric Stress 
and Anxiety in Response to Left Ventricular Assist Device Implantation.
Mean values of biomarkers (leftward y-axes) and symptoms (rightward y-axes) are 
presented as the filled rectangle and the whisker bars represent the 95% confidence interval 
for each time point. Horizontal lines (dashed lines for biomarkers, solid lines for symptoms) 
for each graph represent overall change between pre-implant and 180 days post implant. 
Thresholds for acceptable fit for CFI and TLI are ≥ 0.95, RMSEA = ≤0.06, and SRMR ≤ 
0.08. Abbreviations: BPI = Brief Pain Inventory; CFI = comparative fit indices; lnsT2 = 
natural log of soluble form of suppression of tumorigenicity-2; PHQ9 = 9-item Patient 
Health Questionnaire; RMSEA = root mean square errors of approximation; SRMR = 
standardized root mean square residual; TLI = Tucker-Lewis indices.
Lee et al. Page 17

























Lee et al. Page 18
Table 1:
Pre-implant characteristics of the sample
Characteristic (mean ± SD or n (%)) Sample (n=101)
Patient age (in years) 53.1 ± 13.9
Female 20 (19.8%)
Caucasian 83 (82.2%)
Body Mass Index (kg/m2) 28.9 ± 5.4
Ischemic Etiology 34 (33.7%)
Comorbidities:
    Type II Diabetes Mellitus 41 (40.6%)
    Sleep Apnea/Sleep Disordered Breathing 46 (45.5%)
    Hypertension 52 (51.5%)
    Pulmonary Hypertension 34 (33.7%)
    Atrial Fibrillation 49 (48.5%)
    Chronic Kidney Disease Stage 3 37 (36.6%)
    Chronic Obstructive Pulmonary Disease 22 (21.8%)
Ne York Heart Association Class III/IV 97 (96.0%)
Center Ventricular Ejection Fraction (%) 20.5 ± 2.8
Center Ventricular Internal Diastolic Diameter (cm) 7.4 ± 1.1
Pulmonary Capillary edge Pressure (mm Hg) 23.4 ± 8.6
Right Atrial Pressure (mm Hg) 9.3 ± 4.8
Cardiac Index (by Fick Equation) (L/min/m2) 1.9 ± 0.5
V02 max (L/min) 15.0 ± 4.5
Serum Sodium (mEq/L) 134.4 ± 4.1
Serum Hemoglobin (%) 12.1 ± 2.0
Blood Urea Nitrogen/Creatinine Ratio 22.5 ± 8.3
Continuous Inotropic Support 72 (71.3%)
Intra-Aortic Balloon Pump 43 (42.6%)
Bridge to Transplant 68 (67.3%)
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